FDA Approves New Fixed-Dose Combination Drug, Triumeq (Abacavir Sulfate/Dolutegravir/Lamivudine), to Treat HIV Infection

"On August 22, 2014, FDA approved a new fixed-dose combination product: TRIUMEQ, a combination of dolutegravir (integrase strand transfer inhibitor), abacavir sulfate and lamivudine (both nucleoside analogue reverse transcriptase inhibitors) for the treatment of HIV-1 infection.  "TRIUMEQ alone is not recommended for use in patients with current or past history of resistance to any components of TRIUMEQ. "TRIUMEQ alone is not recommended in patients with resistance-associated integrase substitutions or clinically suspected integrase strand transfer inhibitor resistance because the dose of dolutegravir in TRIUMEQ is insufficient in these subpopulations. See full prescribing information for dolutegravir.  "The recommended dosage regimen of TRIUMEQ in adults is one tablet once daily orally with or without food." The complete label for Triumeq is available at the FDA website. For more information, view the FDA press release.